Dicerna Pharmaceuticals, Inc. DRNA
38.22 +38.22
Day range unavailable
52-week range unavailable
News
businesswire.com Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition LEXINGTON, Mass.--(BUSINESS WIRE)--Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.…- businesswire.com Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition LEXINGTON, Mass.--(BUSINESS WIRE)--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.
businesswire.com Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended…
businesswire.com Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
gurufocus.com Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna Novo Nordisk AS ( NVO , Financial) is shelling out $3.3 billion to buy partner Dicerna Pharmaceuticals Inc. ( DRNA , Financial). That's $38.25 per share in cash, an 80% premium to the $21.28 closing…
prnewswire.com SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA NEW YORK, Nov. 22, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class…
zacks.com Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
prnewswire.com SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc. NEW YORK, Nov. 18, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc.…
newsfilecorp.com SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk New York, New York--(Newsfile Corp. - November 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Dicerna Pharmaceuticals, Inc.…
invezz.com Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80% Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about…
fool.com Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.
investorplace.com LCID, RIVN, FSR: Why Are EV Stocks Down Today? We're taking a look at why EV stocks are down today and there are a couple of reasons shares of investors' favorites are falling. The post LCID, RIVN, FSR: Why Are EV Stocks Down Today?
prnewswire.com Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.…
businesswire.com Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share…
investorplace.com DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna…
benzinga.com Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to…
pulse2.com Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.
marketwatch.com Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.
businesswire.com Novo Nordisk to Acquire Dicerna LEXINGTON, Mass.--(BUSINESS WIRE)--DRNA announces definitive agreement with Novo Nordisk to be acquired for $38.25 per share in cash, which represents total equity value of $3.3 billion
benzinga.com The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Here's a roundup of top developments in the biotech space over the last 24 hours:
benzinga.com Earnings Scheduled For November 9, 2021 Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
benzinga.com The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 Upgrades
benzinga.com Earnings Scheduled For August 9, 2021 Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.- benzinga.com Stocks That Hit 52-Week Highs On Tuesday During Tuesday's morning session, 124 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 145 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 255 companies made new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Friday During Friday's morning session, 235 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday morning saw 244 companies set new 52-week highs.
- benzinga.com Earnings Scheduled For May 6, 2021 Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 136 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 420 companies set new 52-week highs.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 230 companies made new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET Thursday, 371 stocks hit new 52-week highs.
- benzinga.com Earnings Scheduled For February 25, 2021 Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings at $0.23 per share on revenue of $4.78 billion.
- benzinga.com Earnings Scheduled For November 5, 2020 Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly loss at $0.64 per share on revenue of $52.59 million.
benzinga.com Stocks That Hit 52-Week Highs On Friday - benzinga.com 75 Biggest Movers From Yesterday
benzinga.com Stocks That Hit 52-Week Highs On Monday - benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks Which Set New 52-Week High Friday, September 14th
- benzinga.com 55 Biggest Movers From Yesterday
- benzinga.com Stocks Which Set New 52-Week High Yesterday, September 5th
- benzinga.com Stocks Which Set New 52-Week High Yesterday, August 15th
- benzinga.com 10 Stocks With Three-Day Increasing Volume
- benzinga.com 22 Stocks With Three-Day Increasing Volume